At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 332 enrolled
Drug / intervention
Brexpiprazole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Flexible-dose, Double-blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Sep 24, 2019·Updated Jul 18, 2024
In Brief
A Phase 2 clinical trial evaluating Brexpiprazole and Placebo for Borderline Personality Disorder. Completed, enrolled 332 participants across 77 sites in 3 countries.
Detailed Summary
There are currently no pharmacological treatments approved to treat borderline personality disorder (BPD). This trial will be conducted to evaluate the efficacy and safety of brexpiprazole for the treatment of participants diagnosed with BPD to provide a pharmacological treatment for BPD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBorderline Personality Disorder
CountriesSpain, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartOct 2019
Primary CompletionJun 2021
TodayJul 2026
First PostedSep 24, 2019
Enrollment StartOct 17, 2019
Primary CompletionJun 27, 2021
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.8 years ago
Interventions
Brexpiprazoledrug
Tablet
Placeboother
Tablet